

purchase of antiretroviral drugs for treatment of established HIV infection (with the exception nevirapine in PMTCT cases and with prior written approval), occupational exposures, and non-occupational exposures and will not be used for the purchase of machines and reagents to conduct the necessary laboratory monitoring for patient care.

No funds awarded under this announcement shall be used to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug.

Applicants may contract with other organizations under these cooperative agreements, however, applicants must perform a substantial portion of the activities (including program management and operations and delivery of prevention services) for which funds are requested.

The costs that are generally allowable in grants to domestic organizations are likewise allowable to foreign institutions and international organizations, with the following exception;

*Indirect Costs:* With the exception of the American University, Beirut, the Gorgas Memorial Institute, and the World Health Organizations, indirect costs will not be paid (either directly or through a sub-award) to organizations located outside the territorial limits of the United States or to international organizations regardless of their location.

#### **D. Where to Obtain Additional Information**

This and other CDC announcements can be found on the CDC home page Internet address—<http://www.cdc.gov>. Click on "Funding" then "Grants and Cooperative Agreements."

To obtain business management technical assistance, contact: Dorimar Rosado, Grants Management Officer, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341-4146, Telephone number: (770) 488-2782, e-mail: [dpr7@cdc.gov](mailto:dpr7@cdc.gov).

For program technical assistance, contact: Tadesse Wuhib, MD, MPH, CDC Ethiopia, U.S. Embassy, P.O. Box 1014, Entoto Road, Addis Ababa, Ethiopia, Telephone: 251-9-22-00-84 e-mail: [tew7@cdc.gov](mailto:tew7@cdc.gov).

Dated: July 17, 2001.

**John L. Williams,**

*Director, Procurement and Grants Office,  
Centers for Disease Control and Prevention (CDC).*

[FR Doc. 01-18283 Filed 7-20-01; 8:45 am]

**BILLING CODE 4163-18-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Centers for Disease Control and Prevention**

**[Program Announcement 01146]**

#### **Expansion of HIV/AIDS Prevention Activities in the Republic of Kenya; Notice of Availability of Funds**

##### **A. Purpose**

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 2001 funds for a cooperative agreement program for Global AIDS Program.

The purpose of the program is to provide assistance in developing a disease Surveillance program for the control of HIV/AIDS in the country of Kenya, and to support activities to reduce the burden of tuberculosis.

##### **B. Eligible Applicants**

###### *Single Source*

Assistance will be provided only to the Ministry of Health (MOH) of the Country of Kenya. No other applications are solicited.

This announcement is restricted to the MOH or subservient agencies of the government of Kenya as they are the only legislated entity with the authority and responsibility to collect such data for the purpose of the control of HIV/AIDS, communicable disease and the maintenance of public health.

##### **A. Availability of Funds**

Funds are available under this announcement to fund two specific activities with funding amounts identified for each activity. These activities are:

1. HIV/AIDS Surveillance Activities including:

(a) Monitoring of Blood Safety  
(b) Overall monitoring of HIV VCT and Mother to Child Transmission within Kenya—\$500,000

2. Tuberculosis Surveillance and Control as it relates to HIV/AIDS—\$1 million

Each component or program activity for which funds are requested should be specifically identified with Goals, Plan, Objectives, Activities, Method of Evaluation and budget provided. A

summary budget by line item should be provided.

It is expected that the awards will begin on or about September 30, 2001 and will be made for a 12-month budget period within a project period of up to five (5) years. Funding estimates may change.

Continuation awards within an approved project period will be made on the basis of satisfactory progress as evidenced by required reports and the availability of funds.

##### *Use of Funds*

###### *Antiretroviral Drugs*

Funds received from this announcement will not be used for the purchase of antiretroviral drugs for treatment of established HIV infection (with the exception nevirapine in PMTCT cases and with prior written approval), occupational exposures, and non-occupational exposures and will not be used for the purchase of machines and reagents to conduct the necessary laboratory monitoring for patient care.

Applicants may contract with other organizations under these cooperative agreements, however, applicants must perform a substantial portion of the activities including program management and operations and delivery of prevention services for which funds are requested.

The costs that are generally allowable in grants to domestic organizations are likewise allowable to foreign institutions and international organizations, with the following exceptions:

*Indirect Costs:* With the exception of the American University, Beirut, the Gorgas Memorial Institute, and the World Health Organization, indirect costs will not be paid (either directly or through a sub-award) to organizations located outside the territorial limits of the United States or to international organizations regardless of their location.

All requests for funds, including the budget contained in the application, shall be stated in U.S. dollars. Once an award is made, the Department of Health and Human Services (DHHS) will not compensate foreign grantees for currency exchange fluctuations through the issuance of supplemental awards.

###### *Needle Exchange*

No funds appropriated under this Act shall be used to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug.

## D. Where to Obtain Additional Information

This and other CDC announcements can be found on the CDC home page Internet address—<http://www.cdc.gov>. Click on “Funding” then “Grants and Cooperative Agreements.”

To obtain business management technical assistance, contact: Dorimar Rosado, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341-4146, Telephone number (770) 488-2782, E-mail address: [dpr7@cdc.gov](mailto:dpr7@cdc.gov).

For program technical assistance, contact: Lawrence H. Marum, M.D., FAAP, MPH, CDC LIFE Initiative P.O. Box 30137, Nairobi, National AIDS/ASTD Control Programme (NAS COP), P.O. Box 30137, Nairobi, Kenya.

US Mail: Unit 64112, APO, AE 09831-4112, Telephone number: +254-72-721-781 or +254-2-729-549, Fax: +254-2-714-745, E-mail: [Lmarum@nairobi.mimcom.net](mailto:Lmarum@nairobi.mimcom.net).

Dated: July 17, 2001.

**John L. Williams,**

*Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 01-18285 Filed 7-20-01; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Program Announcement 01191]

### Human Immunodeficiency Virus Prevention Intervention Research Studies—Efficacy of Condom Skills Building Demonstrations for Human Immunodeficiency Virus (HIV)/Sexually Transmitted Disease (STD) Prevention Notice of Availability of Funds

#### A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 2001 funds for a cooperative agreement program for efficacy of condom skills building demonstrations for HIV/Sexually Transmitted Disease (STD) prevention. This program addresses the “Healthy People 2010” focus area of HIV.

The purpose of the program is to study condom use skills-building demonstrations for HIV/STD prevention.

#### Research Topic

This announcement seeks research applications aimed at developing and evaluating brief (30 minutes or less), condom skills-building interventions that can be conducted with groups of patients in waiting room settings. Refer to Attachment II in the application kit for additional background information on the research topic.

#### B. Eligible Applicants

Applications may be submitted by public and private nonprofit and for-profit organizations and by governments and their agencies; that is, universities, colleges, research institutions, hospitals, other public and private nonprofit and for-profit organizations, State and local governments or their bona fide agents, including the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of Northern Mariana Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau, and federally recognized Indian tribal governments, Indian tribes, or Indian tribal organizations, small, minority, women-owned businesses.

#### Additional Eligibility Requirements

Eligible applicants must demonstrate:

1. Access to a clinical laboratory capable of conducting urine-based nucleic acid amplification tests (NAATs) for gonorrhea and chlamydia.
2. For this study, the clinic(s) must have at least 180 incident cases of STD over six months among men and at least 180 incident cases of STD over six months among women. STDs among men include gonorrhea, chlamydia, non-gonococcal urethritis (NGU), cervicitis, trichomonas or syphilis. STDs among women include gonorrhea, chlamydia, NGU, cervicitis, trichomonas or syphilis.

**Note:** Title 2 of the United States Code, Chapter 26, Section 1611 states that an organization described in section 501(c)(4) of the Internal Revenue Code of 1986 that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, cooperative agreement, contract, loan, or any other form.

#### C. Availability of Funds

Approximately \$700,000 is available in FY 2001 to fund approximately two to three awards. It is expected that the average award will be \$240,000 per year, ranging from \$190,000 to \$290,000. It is expected that the awards will begin on or about September 30, 2001 and will be made for a 12-month budget period within a project period of

up to three years. Funding estimates may change.

Continuation awards within an approved project period will be made on the basis of satisfactory progress as evidenced by required reports and the availability of funds.

#### 1. Use of Funds

Funds are awarded for a specifically defined purpose and may not be used for any other purpose or program. Funds may be used to support personnel and to purchase equipment, supplies, and services directly related to project activities. Funds may not be used to supplant State or local funds available for HIV Prevention. Funds may not be used to provide direct medical care or prevention case management.

#### 2. Funding Preferences

Funding preference may be given to achieve geographical diversity for condom use skills-building demonstrations in a variety of locations.

#### D. Program Requirements

In conducting activities to achieve the purpose of this program, the recipient will be responsible for the under 1. (Recipient Activities), and CDC will be responsible for the activities listed under 2. (CDC Activities).

##### 1. Recipient Activities:

a. Form a Coordinating Committee including all recipients, to design, implement and evaluate project activities, and wherever appropriate, include participation of State and local health departments.

b. Review the literature on (1) new condom technologies and (2) existing brief, waiting room interventions that have been used in STD/HIV prevention and other health-related areas (e.g., family planning, smoking cessation).

c. Based on existing research, conduct formative research that involves (1) brief, pilot studies to help develop a single condom-use skills-building intervention that can be conducted in a waiting room setting, and (2) brief, pilot studies developing new, less costly ways of following study participants for STD outcomes over time. Prior to implementation, pilot study proposals must be submitted to the local and CDC Institutional Review Boards (IRBs) for review and approval or deferral.

d. Based on the results recipient pilot studies, the Coordinating Committee will develop a single research study protocol, quality assurance mechanisms, training tools, data collection instruments and techniques, specimen collection protocols, and data management procedures that will be used across sites.